Discovery and Preclinical Development of Antigiardiasis Fumagillol Derivatives

Abstract

Giardiasis, caused by the intestinal parasite Giardia lamblia , is a severe diarrheal disease, endemic in poverty-stricken regions of the world, and also a common infection in developed countries. The available therapeutic options are associated with adverse effects, and G. lamblia resistance to the standard-of-care drugs is spreading. Fumagillin, an antimicrosporidiosis drug, is a therapeutic agent with potential for the treatment of giardiasis. However, it exhibits considerable, albeit reversible, toxicity when used to treat immunocompromised microsporidiosis patients.

Topics & Concepts